BIOVECTRA Announces Acquisition of Former Sunovion (Sepracor) Facility

June 23, 2014

BIOVECTRA Announces Acquisition of Former Sunovion (Sepracor) Facility

BIOVECTRA, a specialized cGMP manufacturer, and developer of pharmaceutical ingredients has announced today that it has agreed to purchase the previous Sepracor Canada Limited facility at Windsor, Nova Scotia, for an undisclosed sum.

View Article

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications